Format

Send to

Choose Destination
Curr Opin Gastroenterol. 2012 Nov;28(6):615-20. doi: 10.1097/MOG.0b013e328358d5b9.

Proton pump inhibitors: potential adverse effects.

Author information

1
Sections of Gastroenterology and Health Services Research at the Michael E. DeBakey VAMC; Baylor College of Medicine, Houston, Texas 77030, USA. nabraham@bcm.edu

Abstract

PURPOSE OF REVIEW:

This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia. An epidemiologic framework is applied to assess clinical relevance and reinforce best practice recommendations.

RECENT FINDINGS:

The evidence for PPI adverse events is limited by the absence of Level 1 (randomized controlled trial) studies. The best evidence supports Clostridium difficile and bone fractures in susceptible populations. A substantial reduction in gastrointestinal bleeding risk without increase in cardiovascular events was observed in the COGENT trial when clopidogrel was coprescribed with omeprazole. The risk of pneumonia is inconsistent, and although acute interstitial nephritis, nutritional deficiencies (including B12 and hypomagnesemia), gastric carcinoid and rebound hyperacidity are biologically plausible, studies have failed to demonstrate supportive clinical relevance.

SUMMARY:

Prescribe PPI for robust indications only. Strong data supporting risk of adverse events are lacking; however, exercise caution in the elderly and in patients with other risk factors for bone fractures or C. difficile infection.

PMID:
23010681
DOI:
10.1097/MOG.0b013e328358d5b9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center